These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13988970)

  • 21. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Excretion of poliomyelitis virus types 1, 2 and 3 before and after vaccination with the Sabin vaccine in children's institutions].
    Topciu V; Gherman D; Plavoşin-Babuşceac L; Iutchin I; Munteanu N; Ionesco C
    Arch Roum Pathol Exp Microbiol; 1966 Sep; 25(3):791-8. PubMed ID: 4292260
    [No Abstract]   [Full Text] [Related]  

  • 23. [Complications of polio vaccination with Sabin vaccine].
    Ammundsen E
    Fra Sundhedsstyr; 1968 Mar; 4(25):337-8. PubMed ID: 5758675
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Course of immunity in subjects repeatedly vaccinated with Sabin virus].
    Crovari P; Bori D; De Flora S
    G Ig Med Prev; 1971; 12(1):19-32. PubMed ID: 4340479
    [No Abstract]   [Full Text] [Related]  

  • 26. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent research on the take of attenuated poliomyelitis virus (type I, Sabin LSc strain) in children living in a community with a high level of enteroviral infections].
    DARDANONI L; BRANCATO P; GULLO A
    Riv Ist Sieroter Ital; 1962; 37():428-43. PubMed ID: 13883527
    [No Abstract]   [Full Text] [Related]  

  • 30. A physical property as a virus marker. Difference in avidity of cellulose resin for virulent (Mahoney) and attenuated (LSc, 2ab) strain of type 1 poliovirus.
    HODES HL; ZEPP HD; AINBENDER E
    Virology; 1960 May; 11():306-8. PubMed ID: 14402217
    [No Abstract]   [Full Text] [Related]  

  • 31. Viremia in human and experimental poliomyelitis.
    HORSTMANN DM; McCOLLUM RW; MASCOLA AD; RIORDAN JT
    AMA Arch Intern Med; 1954 Nov; 94(5):859-62. PubMed ID: 13206464
    [No Abstract]   [Full Text] [Related]  

  • 32. Viremia in poliomyelitis.
    HORSTMANN DM
    Bull N Y Acad Med; 1953 Sep; 29(9):736-9. PubMed ID: 13082348
    [No Abstract]   [Full Text] [Related]  

  • 33. Poliomyelitis Viremia.
    Manwaring WH
    Calif Med; 1953 Oct; 79(4):324. PubMed ID: 18731887
    [No Abstract]   [Full Text] [Related]  

  • 34. [Type I poliomyelitis epidemic in France and use of homotypic vaccine (Sabin LSc 2ab). 3. Study of the non-poliomyelitic enteric virus isolated before and after vaccination. Predominance of Coxsackie A7 virus].
    Netter R; Drouhet V; Grist NR; Delpy J
    Arch Gesamte Virusforsch; 1966; 18(1):72-9. PubMed ID: 4294188
    [No Abstract]   [Full Text] [Related]  

  • 35. [On the problem of revaccination against poliomyelitis. Results of a reinfection experiment using the poliovirus type 1, strain "LSc, 2ab (Sabin)". 4 and half years following original vaccination].
    Kuwert E; Posch J; Lagarie G
    Med Klin; 1968 May; 63(18):701-7. PubMed ID: 4305218
    [No Abstract]   [Full Text] [Related]  

  • 36. [Type I poliomyelitis epidemic in France and use of homotypic vaccine (Sabin LSc 2ab) by oral administration. 1. Virological and serological study of clinical cases and viral spread in schools and the environment of patients before oral vaccination].
    Drouhet V; Netter R; Celers J
    Arch Gesamte Virusforsch; 1966; 18(1):49-58. PubMed ID: 4294186
    [No Abstract]   [Full Text] [Related]  

  • 37. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
    Friedrich F
    Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
    Cáceres VM; Sutter RW
    Clin Infect Dis; 2001 Aug; 33(4):531-41. PubMed ID: 11462191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Viremia following poliomyelitis vaccination with type I (Sabin strain LSc, 2ab)].
    SIEGERT R; ENDERS-RUCKLE G; OEHME J; WALLER HD
    Dtsch Med Wochenschr; 1963 Jun; 88():1272-5. PubMed ID: 13988970
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.